Skip to content

Merck & Co. MRK Cumulative amount of fair value hedging adjustment

Cumulative amount of fair value hedging adjustment at other companies

Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$281.24B+31.2%
Enterprise value$324.94B+34.2%
P/E31.5×+19.2×
P/S4.3×+0.9×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s cumulative amount of fair value hedging adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s cumulative amount of fair value hedging adjustment?
Merck & Co. (MRK) reported cumulative amount of fair value hedging adjustment of $57M in Q1 2026.